Modification of treatment strategies over a period of 14 years has markedly reduced cardiac events among post-myocardial infarction patients

Circulation Journal

Volumn 66, Issue 10, 2002, Pages 881-885

  Kinji, Ishikawa ^a   Akio, Kimura ^a   Takaaki, Taniwa ^a   Toshihiko, Takenaka ^a   Takahiro, Hayashi ^a   Ken, Kanamasa ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cardiac events; Recurrent myocardial infarction; Secondary prevention

Indexed keywords

ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NITRIC ACID DERIVATIVE;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BLOOD CLOT LYSIS; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS GRAFT; FEMALE; HEART INFARCTION; HEART MOVEMENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; Q WAVE; RECURRENT DISEASE; SUDDEN DEATH; FIBRINOLYTIC THERAPY; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY; RISK FACTOR; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; UTILIZATION REVIEW;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTILIPEMIC AGENTS; CORONARY ARTERY BYPASS; DEATH, SUDDEN, CARDIAC; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOLYTIC THERAPY; TREATMENT OUTCOME;

EID: 0036791433     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.66.881     Document Type: Article

References (28)

1. Gottlieb S, Goldbourt U, Boyko V, Harpaz D, Mandelzweig L, Khoury Z, et al. Mortality trends in men and women with acute myocardial infarction in coronary care units in Israel: A comparison between 1981-1983 and 1992-1994. Eur Heart J 2000; 21: 284-295.
2. McGovern PG, Jacobs DR Jr, Shahar E, Arnett DK, Folsom AR, Blackburn H, et al. Trends in acute coronary heart disease mortality, morbidity, and medical care from 1985 through 1997: The Minnesota Heart Survey. Circulation 2001; 104: 19-24.
3. Rogers WJ, Canto JG, Lambrew CT, Tiefenbrunn AJ, Kindaid B, Shoultz DA, et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the U.S. from 1990 through 1999: The National Registry of Myocardial Infarction 1,2 and 3. J Am Coll Cardiol 2000; 36: 2056-2063.
4. Hosoda S, Kimata S, Tamura K, Nakamura M, Toshima H, Shibata J, et al. Factors governing re-infarction in patients with myocardial infarction in Japan. Jpn Circ J 1995; 59: 130-136.
5. Ishikawa K, Kanamasa K, Hayashi T, Takenaka T, Inoki T, Katayama K, et al. Drug treatment for secondary prevention of myocardial infarction. J Cardiol 2000; 35: 397-408.
6. Heger JJ, Weyman AE, Wann LS, Rogers EW, Dillon JC, Feigenbaum H. Cross-sectional echocardiographic analysis of the extent of left ventricular asynergy in acute myocardial infarction. Circulation 1980; 61: 1113-1118.
7. Wagner GS, Freye CJ, Palmeri ST, Roark SF, Stack NC, Ideker RE, et al. Evaluation of a QRS scoring system for estimating myocardial infarct size. I. Specificity and observer agreement. Circulation 1982; 65: 342-347.
8. Cupples LA, Gagnon DR, Wong ND, Ostfeld AM, Kannel WB. Preexisting cardiovascular conditions and long-term prognosis after initial myocardial infarction: The Framingham Study. Am Heart J 1993; 125: 863-872.
9. Wood D. European and American recommendations for coronary heart disease prevention. Eur Heart J 1998; 19(Suppl A): A12-A19.
10. Ryan TJ, Antman EM, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, et al. 1999 Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: Executive summary and recommendations. A report of the American College of Cardiology /American Heart Association Task Force on practice guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 1999; 100: 1016-1030.
11. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-106.
12. Stafford RS. Aspirin use is low among United States outpatients with coronary artery disease. Circulation 2000; 101: 1097-1101.
13. Ishikawa K, Kanamasa K, Hama J, Ogawa I, Takenaka T, Naito T, et al. Aspirin plus either dipyridamole or ticlopidine is effective in preventing recurrent myocardial infarction. Jpn Circ J 1997; 61: 38-45.
14. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
15. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998; 339: 489-497.
16. Ishikawa K, Miyataka M, Kanamasa K, Hayashi T, Takenaka T, Inoki T, et al. Retrospective analysis showing less cardiac events in post-myocardial infarction patients treated with metoprolol. Jpn Circ J 2000; 64: 358-364.
17. Krumholz HM, Radford MJ, Wang Y, Chen J, Marciniak TA. Early β-blocker therapy for acute myocardial infarction in elderly patients. Ann Intern Med 1999; 131: 648-654.
18. Heller DA, Ahern FM, Kozak M. Changes in rates of β-blocker use between 1994 and 1997 among elderly survivors of acute myocardial infarction. Am Heart J 2000; 140: 663-671.
19. Ishikawa K, Miyataka M, Kanamasa K, Hayashi T, Takenaka T, Inoki T, et al. β-blockers reduce the incidence of cardiac events in post-myocardial infarction patients. Jpn Heart J 2000; 41: 279-294.
20. Woods KL, Ketley D, Lowy A, Agusti A, Hagn C, Kala R, et al. The European Secondary Prevention Study Group. Beta-blockers and antithrombotic treatment for secondary prevention after acute myocardial infarction: Towards an understanding of factors influencing clinical practice. Eur Heart J 1998; 19: 74-79.
21. Lubsen J, Poole-Wilson PA, Pocock SJ, van Dalen FJ, Baumann J, Kirwan BA, et al. Design and current status of ACTION: A Coronary disease Trial Investigating Outcome with Nifedipine GITS. Eur Heart J 1998; 19(Suppl I): 120-132.
22. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-1331.
23. Ishikawa K, Nakai S, Takenaka T, Kanamasa K, Hama J, Ogawa I, et al. Short-acting nifedipine and diltiazem do not reduce the incidence of cardiac events in patients with healed myocardial infarction. Circulation 1997; 95: 2368-2373.
24. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115-1122.
25. ISIS-4 (Fourth International Study of Infarct Survival) collaborative group. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-685.
26. Ishikawa K, Kanamasa K, Ogawa I, Takenaka T, Naito T, Kamata N, et al. Long-term nitrate treatment increases cardiac events in patients with healed myocardial infarction. Jpn Circ J 1996; 60: 779-788.
27. Nakamura Y, Moss AJ, Brown MW, Kinoshita M, Kawai C for the Multicenter Myocardial Ischemia Research Group. Long-term nitrate use may be deleterious in ischemic heart disease: A study using the databases from two large-scale postinfarction studies. Am Heart J 1999; 138: 577-585.
28. Wufuer M, Ishikawa K, Takenaka T, Kimura A, Hayashi T, Kanamasa K. Relationship between blood pressure and cardiac events in patients with a healed myocardial infarction. Jpn Circ J 2001; 65: 879-886.